维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

8篇 您的检索式：作者名="HARTI D L"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Predicting range of motion after total knee arthroplasty显示文摘	Ritter M A Harty L D Davis K E etal	2003	J Bone Joint Surg Am2003，85，7：	1
	2	Medial screws and cement: a possible mechanical augmentation in total knee arthroplas- ty显示文摘	Ritter M A Harty L D	2004	J Arthroplasty2004，19，5：	1
	3	Simultaneous Bilateral Versus Unilateral Total Hip Arthroplasty :An Outcomes Analysis 显示文摘	Berend M E Ritter M A Harty L D	2005	Journal of Arthroplasty2005，20，4：	1
	4	A clinical comparison of the anterolateral and posterolateral approaches to the hip显示文摘	RITTER M A HARTY L D KEATING M E	2001	Clin Orthop Rdat Res2001，，385：	1
	5	Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs.	Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch	2017	World Journal of Virology2017，6，4：	1
	6	Simultaneoius bilateral versus unilateral total hip arthroplasty an outcomes analysis显示文摘	Berend M E Ritter M A Harty L D	2005	J Arthroplassty2005，20，4：	1
	7	Genetic applications of an inverse polymerase chain reaction 显示文摘	OCHMAN H GERBER A S HARTI D L	1988	Genetics1988，120，：	1
	8	A Clinical Comparison of the Anterolateral and Postero显示文摘	Ritter M A Harty L D Keating M E	2001	Clin Orthop2001，385，：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费